Arrowhead Pharmaceuticals Inc (ARWR) Forecasted to Post Q1 2019 Earnings of ($0.26) Per Share

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) – Equities research analysts at William Blair issued their Q1 2019 EPS estimates for Arrowhead Pharmaceuticals in a report issued on Wednesday. William Blair analyst Y. Xu expects that the biotechnology company will earn ($0.26) per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Arrowhead Pharmaceuticals’ Q2 2019 earnings at ($0.26) EPS, Q3 2019 earnings at ($0.27) EPS and Q4 2019 earnings at ($0.27) EPS.

ARWR has been the subject of several other research reports. ValuEngine cut shares of Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Piper Jaffray Companies raised shares of Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 target price for the company in a report on Monday, November 27th. Cantor Fitzgerald reissued a “hold” rating and set a $2.00 target price (up previously from $1.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, September 15th. BidaskClub cut shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. Finally, Chardan Capital restated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $3.17.

Arrowhead Pharmaceuticals (NASDAQ ARWR) traded down $0.25 during midday trading on Thursday, hitting $3.15. 1,702,102 shares of the company’s stock were exchanged, compared to its average volume of 984,368. Arrowhead Pharmaceuticals has a fifty-two week low of $1.20 and a fifty-two week high of $4.54. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.84 and a quick ratio of 3.84.

Several hedge funds and other institutional investors have recently made changes to their positions in ARWR. Virtu KCG Holdings LLC grew its position in shares of Arrowhead Pharmaceuticals by 115.6% in the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 53,215 shares during the period. Dimensional Fund Advisors LP boosted its position in Arrowhead Pharmaceuticals by 252.2% during the third quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 31,765 shares during the last quarter. LMR Partners LLP acquired a new position in Arrowhead Pharmaceuticals during the second quarter worth about $467,000. Schwab Charles Investment Management Inc. boosted its position in Arrowhead Pharmaceuticals by 10.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock worth $742,000 after acquiring an additional 16,103 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Arrowhead Pharmaceuticals by 3.4% during the first quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock worth $1,226,000 after acquiring an additional 21,654 shares during the last quarter. Institutional investors and hedge funds own 20.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Arrowhead Pharmaceuticals Inc (ARWR) Forecasted to Post Q1 2019 Earnings of ($0.26) Per Share” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/14/arrowhead-pharmaceuticals-inc-arwr-forecasted-to-post-q1-2019-earnings-of-0-26-per-share.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply